1
|
Battisti NML, Sehovic M, Extermann M. Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non–Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older. Clin Lung Cancer 2017; 18:460-471. [DOI: 10.1016/j.cllc.2017.03.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Revised: 03/04/2017] [Accepted: 03/06/2017] [Indexed: 12/25/2022]
|
2
|
Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Clin Transl Oncol 2016; 19:317-325. [PMID: 27492015 DOI: 10.1007/s12094-016-1532-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 07/12/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, non-platinum combinations of third-generation chemotherapeutic agents are considered an alternative therapeutic option for patients who cannot tolerate the toxic effects of platinum compounds. In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-naïve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. PATIENTS AND METHODS A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110 mg/m2 on day 1 and 100 mg/m2 on day 8 plus cisplatin 80 mg/m2 on day 8 every 3 weeks (IC arm) or pemetrexed 500 mg/m2 plus cisplatin 80 mg/m2 on day 1 every 3 weeks (PC arm). The primary endpoint of the study was the overall response rate (ORR). RESULTS The ORR and median progression-free survival (PFS) in the IC arm were 18 % and 3.3 months, respectively, while in the PC arm were 19 % and 4.2 months (p = ns). Median overall survival (OS) was significantly higher in patients with PC (6.9 vs. 10.9; p = 0.013). PC regimen had a better toxicity profile compared to IC, with a statistically significant lower incidence of grade 3/4 neutropenia (3 vs. 31 %; p = 0.0001) and diarrhea (1.6 vs. 14.7 %, p = 0.018). CONCLUSIONS In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. CLINICALTRIALS. GOV IDENTIFIER NCT00614965.
Collapse
Affiliation(s)
- N Kentepozidis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - P Economopoulou
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - Ch Christofyllakis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - L Chelis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - A Polyzos
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - N Vardakis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - F Koinis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - L Vamvakas
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - P Katsaounis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - K Kalbakis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - Ch Nikolaou
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - V Georgoulias
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece
| | - A Kotsakis
- Lung Cancer Working Group of the Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece.
| |
Collapse
|
3
|
Bluthgen MV, Besse B. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. Eur Respir Rev 2015; 24:582-93. [PMID: 26621972 PMCID: PMC9487623 DOI: 10.1183/16000617.00002115] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 03/30/2015] [Indexed: 11/28/2022] Open
Abstract
In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been the standard of care after failure with platinum salts, showing some benefit over best supportive care. Nonetheless, prognosis remains poor and new second-line strategies are urgently needed. Combinations of cytotoxic agents, including rechallenge with platinum salts, do not offer clear benefit over single-agent therapy for the majority of patients. In patients without a known tumoural oncogenic driver mutation, regimens based on combinations of targeted agents have shown promising results; however, a clear role in therapeutic management is yet to be established. Some success has been reported in recent research combining a cytotoxic agent with targeted therapies.In this review, we summarise published data for the various strategies evaluated over the past decade in second-line treatment of NSCLC patients without a known driver mutation. We focus on combination treatments and consider future perspectives, including the need to identify predictive markers to support personalised therapeutic strategies.
Collapse
Affiliation(s)
| | - Benjamin Besse
- Dept of Cancer Medicine, Gustave Roussy, Villejuif, France
| |
Collapse
|
4
|
|
5
|
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 2014; 6:437-49. [PMID: 25364274 PMCID: PMC4211870 DOI: 10.2147/cmar.s63603] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
While there have been advances in treatment options for those with advanced non-small-cell lung cancer, unmet medical needs remain, partly due to the heterogeneity of treatment effect observed among patients. The goals of this literature review were to provide updated information to complement past reviews and to identify a comprehensive set of nongenetic prognostic and predictive baseline factors that may account for heterogeneity of outcomes in advanced non-small-cell lung cancer. A review of the literature between 2000 and 2010 was performed using PubMed, Embase, and Cochrane Library. All relevant studies that met the inclusion criteria were selected and data elements were abstracted. A classification system was developed to evaluate the level of evidence for each study. A total of 54 studies were selected for inclusion. Patient-related factors (eg, performance status, sex, and age) were the most extensively researched nongenetic prognostic factors, followed by disease stage and histology. Moderately researched prognostic factors were weight-related variables and number or site of metastases, and the least studied were comorbidities, previous therapy, smoking status, hemoglobin level, and health-related quality of life/symptom severity. The prognostic factors with the most consistently demonstrated associations with outcomes were performance status, number or site of metastases, previous therapy, smoking status, and health-related quality of life. Of the small number of studies that assessed predictive factors, those that were found to be significantly predictive of outcomes were performance status, age, disease stage, previous therapy, race, smoking status, sex, and histology. These results provide a comprehensive overview of nongenetic prognostic and predictive factors assessed in advanced non-small-cell lung cancer over the last decade. This information can be used to inform the design of future clinical trials by suggesting additional subgroups based on nongenetic factors that may be analyzed to further investigate potential prognostic and predictive factors.
Collapse
Affiliation(s)
| | - Amy M Barrett
- RTI Health Solutions, Research Triangle Park, NC, USA
| | | | | | | | | |
Collapse
|
6
|
Abstract
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or metastatic disease. In this setting the goal of treatment is to prolong survival and to control disease- and treatment-related symptoms. Currently systemic cytotoxic chemotherapy remains the first-line treatment for most patients with stage IV NSCLC, but preferred treatments are now defined by histology and based on the presence of specific molecular abnormalities. In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy are the recommended for patients with EGFR-sensitizing mutations. A small-molecule TKI of anaplastic lymphoma kinase (ALK), crizotinib, showed pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK and it has rapidly entered into daily clinical practice. Currently no agents are specifically approved for the treatment of squamous cell carcinoma of the lung. Second-line treatments include docetaxel, pemetrexed, or erlotinib as single agents. There is a growing evidence that cytotoxics are better than EGFR-TKIs in EGFR wild-type patients. In the setting of the third line, the only approved agent is erlotinib. In elderly patients with good performance status (PS), doublet chemotherapy including platinum should not be excluded, especially for those patients 70-75 years of age without comorbidities. The better selection of patients, the identification of specific predictive biomarkers, a reasonable sequencing of all active and available treatments, including targeted therapies and cytotoxic, may significantly contribute to extend the natural history of stage IV NSCLC.
Collapse
|
7
|
Baykara M, Coskun U, Berk V, Ozkan M, Kaplan MA, Benekli M, Karaca H, Inanc M, Isikdogan A, Sevinc A, Elkiran ET, Demirci U, Buyukberber S. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2013; 13:5119-24. [PMID: 23244121 DOI: 10.7314/apjcp.2012.13.10.5119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
PURPOSE The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. METHODS We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine 1500 mg/m2 and paclitaxel 150 mg/m2 administered every two weeks. RESULTS Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. CONCLUSION The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.
Collapse
Affiliation(s)
- Meltem Baykara
- Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. J Clin Oncol 2012; 30:4501-7. [DOI: 10.1200/jco.2012.43.6758] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). Primary end point was progression-free survival (PFS). A preplanned pooled analysis of the results of this study with those of the NVALT7 study was carried out to assess the impact of carboplatin added to pemetrexed in terms of overall survival (OS). Results From July 2007 to October 2009, 239 patients (arm A, n = 120; arm B, n = 119) were enrolled. Median PFS was 3.6 months for arm A versus 3.5 months for arm B (hazard ratio [HR], 1.05; 95% CI, 0.81 to 1.36; P = .706). No statistically significant differences in response rate, OS, or toxicity were observed. A total of 479 patients were included in the pooled analysis. OS was not improved by the addition of carboplatin to pemetrexed (HR, 90; 95% CI, 0.74 to 1.10; P = .316; P heterogeneity = .495). In the subgroup analyses, the addition of carboplatin to pemetrexed in patients with squamous tumors led to a statistically significant improvement in OS from 5.4 to 9 months (adjusted HR, 0.58; 95% CI, 0.37 to 0.91; P interaction test = .039). Conclusion Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. The benefit observed with carboplatin addition in squamous tumors may warrant further investigation.
Collapse
Affiliation(s)
- Andrea Ardizzoni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Marcello Tiseo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Luca Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrew D. Vincent
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Passalacqua
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Sebastiano Buti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Domenico Amoroso
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrea Camerini
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberto Labianca
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Giovenzio Genestreti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Corrado Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Libero Ciuffreda
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Francesco Di Costanzo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Filippo de Marinis
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Lucio Crinò
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Santo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Pazzola
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Fausto Barbieri
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Nicoletta Zilembo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Ida Colantonio
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Carmelo Tibaldi
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Mattioli
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Mara A. Cafferata
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberta Camisa
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Egbert F. Smit
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| |
Collapse
|
9
|
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 2012; 7:663-71. [PMID: 22425915 DOI: 10.1097/jto.0b013e318244bdd4] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
INTRODUCTION The potential predictive role of BRCA1 and ERCC1 expression levels in patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line platinum-based chemotherapy was investigated. METHODS Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting. RESULTS Low ERCC1 mRNA levels were significantly associated with higher response rate (p = 0.011), longer median progression-free survival (PFS; p = 0.029), and median overall survival (mOS; p = 0.001) after the initiation of the second-line treatment. Similarly, low BRCA1 expression level was significantly correlated with higher response rate (p = 0.022), longer PFS (p = 0.041), and mOS (p = 0.005). In addition, patients with low ERCC1 and BRCA1 mRNA experienced increased median PFS (p = 0.021) and mOS (p < 0.001) in comparison with those who had both genes upregulated. A multivariate analysis revealed that low ERCC1 and low BRCA1 expression levels were significantly associated with increased PFS (hazard ratio [HR]: 0.6; 95% confidence interval [CI]: 0.4-0.8; p = 0.029 and HR: 0.7; 95% CI: 0.6-0.9; p = 0.043, respectively) and OS (HR: 0.5; 95% CI: 0.3-0.7; p = 0.003 and HR: 0.7; 95% CI: 0.6-0.9; p = 0.038, respectively). CONCLUSIONS These results suggest that the ERCC1 and BRCA1 mRNA expression levels in the primary tumor at the time of diagnosis could be used for the prediction of platinum sensitivity in the treatment of NSCLC in the second-line setting. Cross-validation studies are warranted.
Collapse
|
10
|
Factors Affecting Efficacy and Safety of Add-On Combination Chemotherapy for Non-Small-Cell Lung Cancer: A Literature-Based Pooled Analysis of Randomized Controlled Trials. Lung 2012; 190:355-64. [DOI: 10.1007/s00408-012-9379-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Accepted: 01/22/2012] [Indexed: 10/28/2022]
|
11
|
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 2011; 73:1-10. [DOI: 10.1016/j.lungcan.2011.02.022] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Revised: 02/18/2011] [Accepted: 02/27/2011] [Indexed: 11/22/2022]
|
12
|
Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study. Clin Lung Cancer 2011; 12:100-5. [DOI: 10.1016/j.cllc.2011.03.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2010] [Revised: 07/29/2010] [Accepted: 08/24/2010] [Indexed: 11/23/2022]
|
13
|
Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 2010; 10:633. [PMID: 21092076 PMCID: PMC2994826 DOI: 10.1186/1471-2407-10-633] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2010] [Accepted: 11/19/2010] [Indexed: 11/20/2022] Open
Abstract
Background To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Methods Patients pre-treated with front-line platinum-free regimens, were randomized to receive either docetaxel/carboplatin (DC), (docetaxel 50 mg/m2; carboplatin AUC4; both drugs administered on days 1 and 15) or docetaxel single-agent (D), (docetaxel 50 mg/m2 on days 1 and 15). Results Response rate was similar between the two arms (DC vs D: 10.4% vs 7.7%; p = 0.764). After a median follow-up time of 28.0 months for DC arm and 34.5 months for D arm, progression free survival (PFS) was significantly higher in the DC arm (DC vs D:3.33 months vs 2.60 months; p-value = 0.012), while no significant difference was observed in terms of overall survival (OS) (DC vs D: 10.3 months vs 7.70 months; p-value = 0.550). Chemotherapy was well-tolerated and grade III/IV toxicities were relatively infrequent. No toxic deaths were observed. Conclusions This study has not achieved its primary objective of significant OS prolongation with docetaxel/carboplatin combination over single-agent docetaxel in patients who had not received front-line docetaxel; however, the docetaxel/carboplatin combination was associated with a significant clinical benefit in terms of PFS.
Collapse
|
14
|
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010; 2010. [PMID: 20886011 PMCID: PMC2945654 DOI: 10.1155/2010/207084] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Accepted: 07/14/2010] [Indexed: 11/17/2022] Open
Abstract
Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications can prove fatal. Multiple pathogenetic mechanisms have been suggested. Hypersensitivity usually appears after multiple infusions, suggesting type I allergic reactions; however, other types of hypersensitivity also seem to be implicated. Several management options are available to treating physicians: discontinuation of chemotherapy, premedication, prolonging of infusion duration, desensitization protocols, and replacement with a different platinum compound after performing skin tests that rule out cross-reactions among platinum agents.
Collapse
|
15
|
Caponi S, Vasile E, Ginocchi L, Tibaldi C, Borghi F, D’Incecco A, Lucchesi M, Caparello C, Andreuccetti M, Falconel A. Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clin Lung Cancer 2010; 11:320-7. [DOI: 10.3816/clc.2010.n.040] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. Eur J Cancer 2010; 46:735-43. [DOI: 10.1016/j.ejca.2009.12.013] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Revised: 12/01/2009] [Accepted: 12/03/2009] [Indexed: 10/20/2022]
|
17
|
de Lima Araújo LH, Ferreira CG. Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block? J Clin Oncol 2009; 28:e24-5; author reply e26. [PMID: 19933903 DOI: 10.1200/jco.2009.25.1157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Second and third line treatment in non-small cell lung cancer. Crit Rev Oncol Hematol 2009; 71:117-26. [DOI: 10.1016/j.critrevonc.2009.01.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2008] [Revised: 01/28/2009] [Accepted: 01/29/2009] [Indexed: 01/11/2023] Open
|
19
|
Neville A. Lung cancer. BMJ CLINICAL EVIDENCE 2009; 2009:1504. [PMID: 19445746 PMCID: PMC2907801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION Lung cancer is the leading cause of cancer deaths in both men and women, with 80-90% of cases caused by smoking. Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy. Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery. METHODS AND OUTCOMES We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for resectable and unresectable non-small cell lung cancer? What are the effects of treatments for small cell lung cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations, such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS We found 86 systematic reviews and RCTs. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS In this systematic review, we present information relating to the effectiveness and safety of the following interventions: chemotherapy (postoperative or preoperative, dose intensification), continuous hyperfractionated accelerated radiotherapy (CHART), different single-agent chemotherapy regimens, first-line palliative chemotherapy (single or multiple agents), first-line platinum (or non-platinum)-based chemotherapy, molecular-targeted therapy, non-CHART hyperfractionated radiotherapy, palliative care, prophylactic cranial irradiation, second-line chemotherapy (with single or multiple agents), second-line molecular-targeted therapy (with gefitinib or erlotinib), second-line palliative chemotherapy, and thoracic irradiation (with or without chemotherapy).
Collapse
|
20
|
Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AMC, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2009; 27:2038-45. [DOI: 10.1200/jco.2008.19.1650] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PurposeWe performed a randomized phase II trial comparing pemetrexed with pemetrexed plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy.Patients and MethodsMain eligibility criteria were histologic or cytologic proof of advanced non–small-cell lung cancer (NSCLC), relapse more than 3 months after platinum-based chemotherapy, normal organ function, and Eastern Cooperative Oncology Group performance status 0 to 2. Patients were randomly assigned to pemetrexed 500 mg/m2(arm A) or carboplatin area under the curve 5 and pemetrexed 500 mg/m2(arm B), both administered intravenously every 3 weeks. Response assessment was performed every 6 weeks; toxicity assessment was performed every 3 weeks. Primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), overall survival (OS), and toxicity. The study was designed to detect a 33% decrease in the hazard of disease progression in the combination arm (α = 0.05, two-sided log-rank test). Polymorphisms of thymidylate synthase, the reduced folate carrier, γ-glutamyl hydrolase, and methylenetetrahydrofolate reductase (MTHF) were investigated in peripheral WBCs of consenting patients.ResultsTwo hundred forty patients were enrolled. Median TTP was 2.8 months for arm A versus 4.2 months for arm B (hazard ratio, 0.67; 95% CI, 0.51 to 0.89; P = .005). Median OS was 7.6 months and 8.0 months and ORR was 4% and 9% for arms A and B, respectively. Subgroup analyses found adenocarcinoma to be associated with favorable outcome. Toxicities in both arms was negligible, with one potential toxic death in arm A. Patients with MTHFR C677T homozygous mutation had increased progression-free survival compared with patients with wild-type or heterozygous mutations (P = .03).ConclusionPC as second-line treatment for relapsed NSCLC resulted in a significant 33% reduction of the hazard of disease progression as compared with pemetrexed alone.
Collapse
Affiliation(s)
- Egbert F. Smit
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Sjaak A. Burgers
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Bonne Biesma
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Hans J.M. Smit
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Pier Eppinga
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Anne-Marie C. Dingemans
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Markus Joerger
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Jan H. Schellens
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Andrew Vincent
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Nico van Zandwijk
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| | - Harry J.M. Groen
- From the Department of Pulmonary Diseases Vrije Universiteit Medical Centre; Department of Medical Oncology, Netherlands Cancer Institute; Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Data Centre, Amsterdam; Jeroen Bosch Hospital, 's-Hertogenbosch; Rijnstate Hospital, Arnhem; Nij Smellinghe, Drachten; Academisch Ziekenhuis Maastricht, Maastricht; University Medical Centre Groningen, Groningen, the Netherlands; Department of Oncology and Hematology, Cantonal Hospital, St Gallen,
| |
Collapse
|
21
|
Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2009; 27:1836-43. [PMID: 19273711 DOI: 10.1200/jco.2008.17.5844] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Doublet chemotherapy is more effective than single-agent as first-line treatment of advanced non–small-cell lung cancer (NSCLC). As second-line treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival. Methods We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-line treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial. Results Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms (P = .32). Median OS was 37.3 and 34.7 weeks in the doublet and single-agent arms, respectively. Hazard ratio (HR) was 0.92 (95% CI, 0.79 to 1.08). Response rate was 15.1% with doublet and 7.3% with single-agent (P = .0004). Median progression-free survival was 14 weeks for doublet and 11.7 weeks for single agent (P = .0009; HR, 0.79; 95% CI, 0.68 to 0.91). There was no significant heterogeneity among trials for the three efficacy outcomes. Patients treated with doublet chemotherapy had significantly more grade 3 to 4 hematologic (41% v 25%; P < .0001) and grade 3 to 4 nonhematologic toxicity (28% v 22%; P = .034). Conclusion Doublet chemotherapy as second-line treatment of advanced NSCLC significantly increases response rate and progression-free survival, but is more toxic and does not improve overall survival compared to single-agent.
Collapse
Affiliation(s)
- Massimo Di Maio
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Paolo Chiodini
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Vassilis Georgoulias
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Dora Hatzidaki
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Koji Takeda
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Floris M. Wachters
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Vittorio Gebbia
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Egbert F. Smit
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Alessandro Morabito
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Ciro Gallo
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Francesco Perrone
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Cesare Gridelli
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| |
Collapse
|
22
|
Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009; 64:917-24. [PMID: 19221753 DOI: 10.1007/s00280-009-0943-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2008] [Accepted: 01/19/2009] [Indexed: 11/25/2022]
Abstract
BACKGROUND We conducted a prospective phase II trial of IrOx in patients with advanced non-small cell lung cancer to evaluate the efficacy and toxicity. PATIENTS AND METHODS Patients with histologically or cytologically proven non-small cell lung cancer (NSCLC), aged > or =18 years, Eastern Cooperative Oncology Group performance status 0-1, at stage IIIB (pleural effusion)/IV or with recurrent disease not suitable for primary surgical treatment, with no palliative chemotherapy or radiotherapy to the chest or immunotherapy or biologic therapy, the presence of measurable disease by RECIST, and who had given signed written informed consent, were eligible. Treatment consisted of irinotecan 65 mg/m(2) on days 1 and 8 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks. RESULTS A total of 18 patients were enrolled in June and August 2007, the median age was 59 years (47-73). In total, 71 cycles were administered with a median of 4 cycles per patient (range, 1-6 cycles) and 18 patients were evaluable for treatment response. An independent review of tumor responses gave an overall response rate of 27.7% (CR: 0, PR: 5/18; 95% CI, 7-48.4%) by intent-to-treat analysis. The median overall survival of all patients was 14 months and the median time-to-progression was 4.2 months (95% CI, 1.959-6.441). The most common grade 3/4 toxicities were diarrhea (7% of all cycles) and neutropenia (5.6% of all cycles). Grade 3 peripheral neuropathy occurred in one patient and one patient died due to sepsis. CONCLUSION This study suggests that IrOx combination therapy has moderate activity with a tolerable toxicity profile. However, it was not warranted to evaluate further this regimen as first-line treatment for patients with advanced or metastatic NSCLC using the current dosages and schedule.
Collapse
Affiliation(s)
- Myung Hee Chang
- Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. Lung Cancer 2009; 63:251-8. [DOI: 10.1016/j.lungcan.2008.05.027] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2008] [Revised: 05/21/2008] [Accepted: 05/25/2008] [Indexed: 11/12/2022]
|
24
|
Gebbia V. Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer? Expert Opin Pharmacother 2008; 9:1321-37. [PMID: 18473707 DOI: 10.1517/14656566.9.8.1321] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment. OBJECTIVE An overview of the state of the art of second-line therapeutic options is presented. METHODS The scope of the review is to give an update on the therapeutic options currently available for the second-line treatment of patients with advanced non-small cell lung cancer. RESULTS AND CONCLUSIONS Among chemotherapeutic drugs docetaxel and pemetrexed have been approved for second-line treatment of advanced non-small cell lung cancer. Although the drugs are equiactive in terms of response rate and survival parameters the latter has a clear-cut advantage in terms of tolerability and quality of life. Therefore, pemetrexed is considered the best second-line therapeutic option in order to avoid severe side effects. Among biologic agents the tyrosine kinase inhibitors gefinitib and erlotinib have been largely tested, but only the latter has been approved for second- and third-line treatment. Erlotinib has been reported to be particularly active in patients with adenocarcinoma, in females, in patients of Asian ethnicity and in epidermal growth factor receptor mutations and it is also active in the third-line setting. At present, no direct head to head comparison of erlotinib with any chemotherapeutic agent has been performed. A rational decision tree may therefore include pemetrexed or docetaxel (the former preferred for tolerability) or erlotinib as standard second-line therapy. Erlotinib has been also shown to be active as third-line treatment: however, in cases of patients with clinical characteristics suggesting a good response to tyrosine kinase inhibitors, erlotinib may be employed in an earlier phase.
Collapse
Affiliation(s)
- Vittorio Gebbia
- Medical Oncology University of Palermo, Department of Experimental Oncology and Clinical Applications, Palermo, Italy.
| |
Collapse
|
25
|
Abstract
After failure of first-line chemotherapy for advanced non-small cell lung cancer, many patients remain candidates to receive further antitumor treatment. To guide clinical management of these patients and to suggest priorities for clinical research, an International Panel of Experts met in Naples (Italy) in April 2007. Results and evidence-based conclusions are presented in this article. Single-agent chemotherapy with docetaxel or pemetrexed is the recommended option for unselected patients with performance status 0 to 2 who are candidates for second-line chemotherapy for advanced non-small cell lung cancer. Docetaxel has demonstrated superiority compared with best supportive care. Pemetrexed has been shown to be noninferior to docetaxel, with a more favorable toxicity profile. Erlotinib is effective in pretreated patients, and can be given second-line in patients not suitable or intolerant to chemotherapy, and in all patients as third-line treatment after failure of second-line chemotherapy. Gefitinib failed to show superiority to placebo as second- or third-line treatment, but it has been shown to be noninferior to docetaxel. In selected patients such as lifetime nonsmokers or those of East-Asian ethnicity, erlotinib, or gefitinib (where licensed) may be considered as second-line treatment even if they are fit for chemotherapy. Best supportive care in addition to active treatment remains important for all patients, but may be the exclusive option for patients unsuitable for more aggressive therapy. Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents.
Collapse
|
26
|
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, León L, Lázaro M, Grande C, Mel JR, Ramos M, Salgado M, Casal J. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anticancer Drugs 2007; 18:1201-6. [PMID: 17893521 DOI: 10.1097/cad.0b013e328273bbce] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The current report aims to evaluate the efficacy and safety profile of a biweekly administration of docetaxel and vinorelbine to patients with advanced non-small cell lung cancer, who had previously been treated for this disease. In a prospective, multicenter, open-label, phase II trial, patients received 40 mg/m of docetaxel and 20 mg/m of vinorelbine on days 1 and 15, every 28 days. Treatment continued for up to a maximum of six cycles, unless disease progression or unacceptable toxicity occurred, or consent was withdrawn. Fifty patients were enrolled in the study and they received 174 cycles of chemotherapy, with a median of three cycles per patient. All patients were evaluated for efficacy and toxicity in an intention-to-treat analysis. The overall response rate was 10% [95% confidence interval (CI): 1-19], including one complete response (2%) and four partial responses (8%). Previous chemotherapy of 80% of the responders included paclitaxel. Median time to disease progression was 2.7 months (95% CI: 2.2-4.3) and median overall survival was 6.5 months (95% CI: 2.5-9.2). The survival rates at 1 and 2 years were 18% (95% CI: 7-29) and 4% (95% CI: 0-10), respectively. The most frequent severe toxicities were neutropenia (20% of patients) and leukopenia (8% of patients). Other toxicities appeared in 4% or fewer of the patients. Biweekly administration of docetaxel and vinorelbine is feasible as a second-line treatment for non-small cell lung cancer patients, but its level of activity and toxicity does not suggest any advantage compared with the results obtained with single-agent docetaxel in the same setting.
Collapse
|
27
|
Takiguchi Y, Moriya T, Asaka-Amano Y, Kawashima T, Kurosu K, Tada Y, Nagao K, Kuriyama T. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Lung Cancer 2007; 58:253-9. [PMID: 17658654 DOI: 10.1016/j.lungcan.2007.06.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Revised: 06/04/2007] [Accepted: 06/11/2007] [Indexed: 11/20/2022]
Abstract
Even with the standard first-line chemotherapy, advanced non-small cell lung cancer (NSCLC) recurs in most cases. The purpose of this study is to develop a new chemotherapeutic regimen for patients with NSCLC that has relapsed or was refractory to previous chemotherapy. Patients with proven NSCLC refractory or recurrent after previous single-regimen chemotherapy, PS of 0-2, age of 15 years or older, adequate organ functions and measurable lesions were treated with irinotecan at 60 mg/m(2) and cisplatin at 25 mg/m(2) with 1000 ml hydration on day 1. This administration, considered as one cycle, was repeated every week without rest unless encountering defined skip and dose-reduction criteria. The treatment was administered for six cycles over a 49-day period, both median values, to 48 patients, with a response rate of 26%, progression free and median survival times of 3 and 11 months, respectively, and a 1-year survival rate of 46%. The most frequent grade 3 or 4 toxicities were neutropenia, anaemia and nausea, which were manageable. Subset analyses suggested that the response rate was independent of response to the first-line chemotherapy. In conclusion, second-line chemotherapy of weekly irinotecan and cisplatin with minimum hydration seemed effective, with tolerable toxicity, and is potentially useful irrespective of the outcome of previous chemotherapy.
Collapse
Affiliation(s)
- Yuichi Takiguchi
- Department of Respirology (B2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. J Thorac Oncol 2006. [DOI: 10.1097/01243894-200611000-00009] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. J Thorac Oncol 2006. [DOI: 10.1097/01243894-200611000-00021] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Noble J, Ellis P, Mackay J, Evans W. Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. J Thorac Oncol 2006. [DOI: 10.1016/s1556-0864(15)31641-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. J Thorac Oncol 2006. [DOI: 10.1016/s1556-0864(15)31629-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
32
|
|
33
|
Affiliation(s)
- R A Stahel
- Clinic and Policlinic of Oncology, University Hospital, Zürich, Switzerland
| |
Collapse
|
34
|
Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V. A Retrospective Analysis of Second-Line Chemotherapy or Best Supportive Care in Patients with Advanced-Stage Non–Small-Cell Lung Cancer. Clin Lung Cancer 2006; 8:49-55. [PMID: 16870046 DOI: 10.3816/clc.2006.n.033] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND We retrospectively evaluated the clinical characteristics and outcome of patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled in first-line chemotherapy trials conducted by our group with respect to receiving or not receiving subsequent treatment. PATIENTS AND METHODS Data were collected from 634 patients with stage IIIB/IV NSCLC treated with platinum and nonplatinum agent-based first-line regimens. Patient survival was calculated from the day of registration to first-line chemotherapy trials (OS1) as well as from the day of first-line treatment failure or the initiation of second-line chemotherapy (OS2) until death. The decision for administering second-line chemotherapy was, in all cases, at the discretion of the physician. Two hundred twenty-four patients (35.3%) received second-line chemotherapy (second-line group) in the context of second-line clinical trials run by the same group, and 410 (64.7%) received best supportive care (BSC group). There were significant differences between second-line and BSC groups in terms of age, histology, early discontinuation of first-line chemotherapy, and performance status after first-line treatment. RESULTS Three (1.3%) complete and 25 (11.2%) partial responses to second-line chemotherapy were observed for an overall response rate of 12.5% (95% confidence interval, 8.2%-16.8%). The median OS1 was 13 months and 7 months (P < 0.001) and the OS2, 7 months and 3 months (P < 0.001) for the second-line and BSC groups, respectively. Multivariate analysis revealed that good performance status, disease stage IIIB, response to first-line treatment, and late termination of first-line chemotherapy were significantly associated with increased survival. The administration of second-line chemotherapy was also independently correlated with better outcome. CONCLUSION The second-line chemotherapy and BSC groups represent different populations of patients with NSCLC. Factors indicative of increased probability of survival could be used to identify the subgroup of patients most likely to benefit from second-line chemotherapy.
Collapse
Affiliation(s)
- Dora Hatzidaki
- Department of Medical Oncology, University General Hospital of Heraklion, Greece
| | | | | | | | | | | |
Collapse
|
35
|
Kim HT, Han JY, Lee DH, Chun JH, Lee HG, Lee JJ, Kim HY, Lee SY, Lee JS. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer 2006; 107:799-805. [PMID: 16826586 DOI: 10.1002/cncr.22063] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Irinotecan (1) and cisplatin (P) are active chemotherapy agents with clinical synergy in non-small-cell lung cancer (NSCLC). We evaluated the efficacy of IP regimen as a salvage treatment of patients with NSCLC that progressed after nonplatinum-containing regimen(s). METHODS Eligibility required histologically confirmed NSCLC, bidimensionally measurable disease, ECOG PS 0-2, and progressive disease after nonplatinum-based chemotherapy. Treatment consisted of I (65 mg/m2) and P (30 mg/m2) i.v. on Days 1 and 8 of a 21-day cycle, for a maximum of 6 cycles. An informed consent was obtained from all patients. RESULTS Between August 2002 and May 2004, 32 patients with median age of 56 years (range, 42-74) were enrolled. Twenty-four (75%) patients were men, and 28 (88%) had ECOG PS 0 or 1. Twenty-five patients had adenocarcinoma and 6 had squamous-cell carcinoma. All patients were evaluated for response and toxicity, and the response rate was 40.6%. After a median follow-up of 18.5 months, the median survival time was found to be 9.3 months, with a 1-year survival rate of 43.8%. Toxicities were moderate and manageable, with 47% G3 and 9% G4 neutropenia, 19% G3 diarrhea, and 22% G3 asthenia. There was no G4 nonhematologic toxicity. CONCLUSIONS The irinotecan and cisplatin combination is an active and well-tolerated regimen for the patients with advanced NSCLC that progressed after nonplatinum-containing regimen(s).
Collapse
Affiliation(s)
- Heung T Kim
- Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|